Targeting C-type lectin receptors for cancer immunity

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Yan, Huimin ^a,b   Kamiya, Tomomori ^a,c   Suabjakyong, Papawee ^a,d   Tsuji, Noriko M ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b Fifth Hospital of Shijiazhuang   (China)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

C type lectin receptors; Cancer immunity; Immunoregulation; Innate immunity

Indexed keywords

C TYPE LECTIN RECEPTOR; DECTIN 1; INFLAMMASOME; LECTIN RECEPTOR; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; DENDRITIC CELL; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84938505704     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00408     Document Type: Review

References (99)

1. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod-and IFN-a-mediated antitumor reactivity. J Immunol (2012) 188:1583-91. 10.4049/jimmunol.1102437.
2. Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol (2013) 4:490. 10.3389/fimmu.2013.00490.
3. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene (2008) 27:218-24. 10.1038/sj.onc.1210904.
4. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 11:373-84. 10.1038/ni.1863.
5. van Vliet SJ, Aarnoudse CA, Broks-van den Berg VC, Boks M, Geijtenbeek TB, van Kooyk Y. MGL-mediated internalization and antigen presentation by dendritic cells: a role for tyrosine-5. Eur J Immunol (2007) 37:2075-81.
6. Hardison SE, Brown GD. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol (2012) 13:817-22. 10.1038/ni.2369.
7. Miyake Y, Toyonaga K, Mori D, Kakuta S, Hoshino Y, Oyamada A, et al. C-type lectin MCL is an FcRγ-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity (2013) 38:1050-62. 10.1016/j.immuni.2013.03.010.
8. Koizumi Y, Toma C, Higa N, Nohara T, Nakasone N, Suzuki T. Inflammasome activation via intracellular NLRs triggered by bacterial infection. Cell Microbiol (2012) 14(2):149-54. 10.1111/j.1462-5822.2011.01707.x.
9. Chan YK, Gack MU. RIG-I-like receptor regulation in virus infection and immunity. Curr Opin Virol (2015) 12C:7-14. 10.1016/j.coviro.2015.01.004.
10. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects. Science (2013) 341(6152):1390-4. 10.1126/science.1244040.
11. Weis WI, Taylor ME, Drickamer K. The C-type lectin superfamily in the immune system. Immunol Rev (1998) 163:19-34.
12. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J (2005) 272:6179-217.
13. Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity (2011) 34:651-64. 10.1016/j.immuni.2011.05.001.
14. Denda-Nagai K, Aida S, Saba K, Suzuki K,Moriyama S, Oo-Puthinan S, et al. Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens by dendritic cells. J Biol Chem (2010) 285:19193-204. 10.1074/jbc.M110.113613.
15. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk B, et al. Mycobacteria target DC-SIGN to suppress dendriticcell function. J Exp Med (2003) 197:7-17.
16. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 72:3125-30. 10.1158/0008-5472.CAN-11-4094.
17. Wang W, Guo H, Geng J, Zheng X, Wei H, Sun R, et al. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escaping from NK cell attack. J Biol Chem (2014) 289:33311-9. 10.1074/jbc.M114.603464.
18. Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol (2012) 30: 491-529. 10.1146/annurev-immunol-031210-101352.
19. Zhu LL, Zhao XQ, Jiang C, You Y, Chen XP, Jiang YY, et al. C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity (2013) 39(2):324-34. 10.1016/j.immuni.2013.05.017.
20. Ifrim DC, Joosten LA, Kullberg BJ, Jacobs L, Jansen T, Williams DL, et al. Candida albicans Primes TLR Cytokine Responses through a Dectin-1/Raf-1-Mediated Pathway. J Immunol (2013) 190:4129-35. 10.4049/jimmunol.1202611.
21. Yonekawa A, Saijo S, Hoshino Y, Miyake Y, Ishikawa E, Suzukawa M, et al. Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. Immunity (2014) 41:402-13. 10.1016/j.immuni.2014.08.005.
22. Behler F, Steinwede K, Balboa L, Ueberberg B, Maus R, Kirchhof G, et al. Role of Mincle in alveolar macrophage-dependent innate immunity against mycobacterial infections in mice. J Immunol (2012) 189:3121-9. 10.4049/jimmunol.1201399.
23. Yan H, Ohno N, Tsuji NM. The role of C-type lectin receptors in immune homeostasis. Int Immunopharmacol (2013) 16(3):353-7. 10.1016/j.intimp.2013.04.013.
24. Marshall AS, Willment JA, Pyz E, Dennehy KM, Reid DM, Dri P, et al. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol (2006) 36:2159-69.
25. Lambert AA, Barabé F, Gilbert C, Tremblay MJ. DCIR-mediated enhancement of HIV-1 infection requires the ITIM-associated signal transduction pathway. Blood (2011) 117: 6589-99. 10.1182/blood-2011-01-331363.
26. Geijtenbeek TB, Gringhuis SI. Signaling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol (2009) 9:465-79. 10.1038/nri2569.
27. Drummond RA, Brown GD. Signalling C-type lectins in antimicrobial immunity. PLoS Pathog (2013) 9:e1003417. 10.1371/journal.ppat.1003417.
28. Hoving JC, Wilson GJ, Brown GD. Signalling C-type lectin receptors, microbial recognition and immunity. Cell Microbiol (2014) 16:185-94. 10.1111/cmi.12249.
29. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, et al. Syk-dependent cytokine induction by dectin-1 reveals a novel pattern recognition pathway for C-type lectins. Immunity (2005) 22:507-17.
30. Hara H, Saito T. CARD9 versus CARMA1 in innate and adaptive immunity. Trends Immunol (2009) 30(5):234-42. 10.1016/j.it.2009.03.002.
31. Sato K, Yang XL, Yudate T, Chung JS, Wu J, Luby-Phelps K, et al. Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses. J Biol Chem (2006) 281:38854-66.
32. Yamasaki S, Ishikawa E, Sakuma M, Ogata K, Saito T. Mincle is an ITAM-couples activating receptor that senses damaged cells. Nat Immunol (2008) 9:1179-88. 10.1038/ni.1651.
33. Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T, et al. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses. Nat Immunol (2015) 16(6):642-52. 10.1038/ni.3155.
34. del Fresno C, Soulat D, Roth S, Blazek K, Udalova I, Sancho D, et al. Interferon-ß production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity (2013) 38(6):1176-86. 10.1016/j.immuni.2013.05.010.
35. Leibundgut-Landmann S, Osorio F, Brown GD, Reis e Sousa C. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood (2008) 112:4971-80. 10.1182/blood-2008-05-158469.
36. Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity (2010) 32:681-91. 10.1016/j.immuni.2010.05.001.
37. Desel C, Werninghaus K, Ritter M, Jozefowski K, Wenzel J, Russkamp N, et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One (2013) 8:e53531. 10.1371/journal.pone.0053531.
38. Xu S, Huo J, Lee KG, Kurosaki T, Lam KP. Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells. J Biol Chem (2009) 284:7038-46. 10.1074/jbc.M806650200.
39. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B, van der Vlist M, Boekhout T, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1ß via a noncanonical caspase-8 inflammasome. Nat Immunol (2012) 13: 246-54. 10.1038/ni.2222.
40. Lambert AA, Barabé F, Gilbert C, Tremblay MJ. DCIR-mediated enhancement of HIV-1 infection requires the ITIM-associated signal transduction pathway. Blood (2011) 117:6589-99. 10.1182/blood-2011-01-331363.
41. Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol (2014) 33:853-863.e5. 10.1016/j.jaci.2013.09.02.
42. Jahn PS, Zanker KS, Schmitz J, Dzionek A. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation. Cell Immunol (2010) 265(1):15-22. 10.1016/j.cellimm.2010.06.005.
43. Chappell CP, Giltiay NV, Draves KE, Chen C, Hayden-Ledbetter MS, Shlomchik MJ, et al. Targeting antigens through blood dendritic cell antigen 2 on plasmacytoid dendritic cells promotes immunologic tolerance. J Immunol (2014) 192:5789-801. 10.4049/jimmunol.1303259.
44. Cai M, Wu J, Mao C, Ren J, Li P, Li X, et al. A Lectin-EGF antibody promotes regulatory T cells and attenuates nephrotoxic nephritis via DC-SIGN on dendritic cells. J Transl Med (2013) 11:103. 10.1186/1479-5876-11-103.
45. Zhou Y, Kawasaki H, Hsu SC, Lee RT, Yao X, Plunkett B,et al. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat Med (2010) 16:1128-33. 10.1038/nm.2201.
46. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self-and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 209:109-21. 10.1084/jem.20110399.
47. Kawashima S, Hirose K, Iwata A, Takahashi K, Ohkubo A, Tamachi T, et al. ß-glucan curdlan induces IL-10-producing CD4+ T cells and inhibits allergic airway inflammation. J Immunol (2012) 189(12):5713-21. 10.4049/jimmunol.1201521.
48. Karumuthil-Melethil S, Gudi R, Johnson BM, Perez N, Vasu C. Fungal ß-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response. J Immunol (2014) 193:3308-21. 10.4049/jimmunol.1400186.
49. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol (2014) 15(11):e493-503. 10.1016/S1470-2045(14)70263-3.
50. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005) 54:187-207.
51. Nonaka M, Ma BY, Murai R, Nakamura N, Baba M, Kawasaki N, et al. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol (2008) 180:3347-56.
52. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem (2011) 286: 22403-413. 10.1074/jbc.M110.215301.
53. Mortezai N, Behnken HN, Kurze AK, Ludewig P, Buck F, Meyer B, et al. Tumor-associated Neu5Ac-Tn and Neu5Gc-Tn antigens bind to C-type lectin CLEC10A (CD301, MGL). Glycobiology (2013) 23:844-52. 10.1093/glycob/cwt021.
54. Aarnoudse CA, Vallejo JJG, Saeland E, Van Kooyk Y. Recognition of tumor glycans by antigen-presenting cells. Current Opinion in Immunology (2006) 18:105-11.
55. Napoletano C, Zizzari IG, Rughetti A, Rahimi H, Irimura T, Clausen H, et al. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J Immunol (2012) 42(4):936-45. 10.1002/eji.201142086.
56. Chieppa M, Bianchi G, Doni A, Del Prete A, Sironi M, Laskarin G, et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. Journal of Immunology (2003) 171:4552-60.
57. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. Journal of Immunology (2000) 165:3730-41.
58. Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol (2010) 2010:547179. 10.1155/2010/547179.
59. Terada M, Khoo KH, Inoue R, Chen CI, Yamada K, Sakaguchi H, et al. Characterization of oligosaccharide ligands expressed on SW1116 cells recognized by mannan-binding protein. A highly fucosylated polylactosamine type N-glycan. J Biol Chem (2005) 280:10897-913.
60. Kawasaki N, Lin CW, Inoue R, Khoo KH, Kawasaki N, Ma BY, et al. Highly fucosylated N-glycan ligands for mannan-binding protein expressed specifically on CD26 (DPPVI) isolated from a human colorectal carcinoma cell line, SW1116. Glycobiology (2009) 19:437-50. 10.1093/glycob/cwn158.
61. Nonaka M, Imaeda H, Matsumoto S, Yong Ma B, Kawasaki N, Mekata E, et al. Mannan-binding protein, a C-type serum lectin, recognizes primary colorectal carcinomas through tumor-associated Lewis glycans. J Immunol (2014) 192:1294-301. 10.4049/jimmunol.1203023.
62. Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev immunol (2006) 6:33-43.
63. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, et al. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature (2011) 472(7344):471-5. 10.1038/nature10071.
64. Chiba S, Ikushima H, Ueki H, Yanai H, Kimura Y, Hangai S, et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumorresponses. Elife (2014) 3:e04177. 10.7554/eLife.04177.
65. Guery L, Dubrot J, Lippens C, Brighouse D, Malinge P, Irla M, et al. Ag-Presenting CpG-Activated pDCs Prime Th17 Cells That Induce Tumor Regression. Cancer Res (2014) 74:6430-40. 10.1158/0008-5472.CAN-14-1149.
66. Riboldi E, Daniele R, Parola C, Inforzato A, Arnold PL, Bosisio D, et al. Human C-type Lectin Domain Family 4, Member C (CLEC4C/BDCA-2/CD303) Is a Receptor for Asialo-galactosyl-oligosaccharides. J Biol Chem (2011) 286:35329-33. 10.1074/jbc.C111.290494.
67. van Vliet SJ, Aarnoudse CA, Broks-van den Berg VC, Boks M, Geijtenbeek TB, van Kooyk Y. MGL-mediated internalization and antigen presentation by dendritic cells: a role for tyrosine-5. Eur J Immunol (2007) 37(8):2075-81.
68. Napoletano C, Zizzari IG, Rughetti A, Rahimi H, Irimura T, Clausen H, et al. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J Immunol (2012) 42(4):936-45. 10.1002/eji.201142086.
69. Chen H, Yuan B, Zheng Z, Liu Z, Wang S. Lewis X oligosaccharides-heparanase complex targeting to DCs enhance antitumor response in mice. Cell Immunol (2011) 269(2):144-8. 10.1016/j.cellimm.2011.03.021.
70. Unger WW, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, et al. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release (2012) 160(1):88-95. 10.1016/j.jconrel.2012.02.007.
71. Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Burgdorf S, Saeland E, et al. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur J Immunol (2011) 41(4):916-25. 10.1002/eji.201040762.
72. He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, et al. Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity. J Immunol (2007) 178(10):6259-67.
73. Masuda Y, Inoue M, Miyata A, Mizuno S, Nanba H. Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol (2009) 9:620-6. 10.1016/j.intimp.2009.02.005.
74. Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, et al. ß-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol (2013) 43(5):1220-30. 10.1002/eji.201242841.
75. Chiba S, Ikushima H, Ueki H, Yanai H, Kimura Y, Hangai S, et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumorresponses. Elife (2014) 3 :e04177. 10.7554/eLife.04177.
76. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today (1997) 18(10):493-7.
77. Dominguez-Soto A, Sierra-Filardi E, Puig-Kröger A, Pérez-Maceda B, Gómez-Aguado F, Corcuera MT, et al. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol (2011) 186(4):2192-200. 10.4049/jimmunol.1000475.
78. Nonaka M, Ma BY, Murai R, Nakamura N, Baba M, Kawasaki N, et al. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol (2008) 180(5):3347-56.
79. Arteta B, Lasuen N, Lopategi A, Sveinbjörnsson B, Smedsrød B, Vidal-Vanaclocha F. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology (2010) 51(6):2172-82. 10.1002/hep.23590.
80. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 41(1):49-61. 10.1016/j.immuni.2014.06.010.
81. Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol (2010) 2010:547179. 10.1155/2010/547179.
82. Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res (2014) 74(13):3418-28. 10.1158/0008-5472.CAN-13-2690.
83. Lu S, Bevier M, Huhn S, Sainz J, Lascorz J, Pardini B, et al. Genetic variants in C-type lectin genes are associated with colorectal cancer susceptibility and clinical outcome. Int J Cancer (2013) 133(10):2325-33. 10.1002/ijc.28251.
84. Xu YF, Liu WL, Dong JQ, Liu WS, Feng QS, Chen LZ, et al. Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in cantonese. BMC Med Genet (2010) 11:161. 10.1186/1471-2350-11-161.
85. Zanetti KA, Haznadar M, Welsh JA, Robles AI, Ryan BM, McClary AC, et al. 3'-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res (2012) 72(6):1467-77. 10.1158/0008-5472.CAN-11-3073.
86. Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, et al. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res (2010) 16(21):5153-64. 10.1158/1078-0432.CCR-10-0820.
87. Masuda Y, Inoue H, Ohta H, Miyake A, Konishi M, Nanba H. Oral administration of soluble ß-glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. Int J Cancer (2013) 133(1):108-19. 10.1002/ijc.27999.
88. Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1->3),(1->4)-D-beta-glucan. Leuk Res (2005) 29:679-83.
89. Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J, et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy (1993) 6(1):13-8.
90. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res (2009) 29(7) :2739-46.
91. Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, Picco G, et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res (2007) 67(17):8358-67.
92. Singh SK, Streng-Ouwehand I, Litjens M, Saeland E, van Kooyk Y. Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. Int J Cancer (2011) 128(6):1371-83. 10.1002/ijc.25458
93. Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Burgdorf S, Saeland E, et al. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur J Immunol (2011) 41(4): 916-25. 10.1002/eji.201040762.
94. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res (2005) 65(15):7007-12.
95. Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother (2007) 30(7):715-26.
96. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 118(6):2098-110. 10.1172/JCI34584
97. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, et al. Targeted Delivery of a-Galactosylceramide to CD8a+ Dendritic Cells Optimizes Type I NKT Cell-Based Antitumor Responses. J Immunol (2014) 193(2):961-9. 10.4049/jimmunol.1303029.
98. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 372(21):2018-28. 10.1056/NEJMoa1501824.
99. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 372(21):2006-17. 10.1056/NEJMoa1414428.